Glofitamab and epcoritamab for large B cell lymphoma: a real-world retrospective UK analysis of efficacy, tolerability, and impact of treatment sequencing - PubMed
3 hours ago
- #Large B Cell Lymphoma
- #Bispecific Antibodies
- #Real-World Evidence
- Glofitamab and epcoritamab are CD3xCD20 bispecific antibodies used for relapsed/refractory large B cell lymphoma, with real-world UK data from 332 patients across 34 centers.
- The patient cohort was high-risk: 55% had primary refractory disease, 25% had ECOG ≥2, 50% had prior CAR-T therapy, and 78% were ineligible for pivotal trials.
- Among treated patients, cytokine release syndrome occurred in 28%, mostly grade 1/2. Overall response rate was 43% and complete response rate was 24% (43% in trial-eligible patients).
- Median progression-free survival was 3.1 months and median overall survival was 6.9 months. For patients not completing cycle 2, 6-month overall survival was 4%.
- Factors associated with worse outcomes included refractoriness to prior treatment, elevated LDH, recent bendamustine exposure, and higher ECOG scores.